NCT04774718进行中（未招募）1 期
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 42
- 试验地点
- 67
- 主要终点
- Percentage of Participants with Adverse Events
研究概览
简要总结
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of CNS or solid tumors with documented evidence of ALK gene fusions as assessed centrally through the use of the investigational F1CDx assay or based on pre-existing NGS test results
- •Disease status: prior treatment proven to be ineffective (i.e. relapsed or refractory), or for whom there is no satisfactory standard treatment available. Disease should be measurable and evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or Response Assessment in Neuro-oncology criteria (RANO) +/- bone marrow criteria for primary CNS tumors or International Neuroblastoma Response Criteria (INRC)
- •Available tumor tissue for submission to the Sponsor from active disease, obtained subsequent to last anti-cancer therapy regimen administered and obtained prior to study enrollment (preferred option), or archival tumor tissue from original diagnosis, or willingness to undergo a core or excisional biopsy sample collection prior to enrollment
- •For participants < 16 years old, Lansky Performance Status >/= 50%
- •For participants >/= 16 years old, Karnofsky Performance Status >/= 50%
- •Adequate bone marrow function as defined by the protocol within at least 28 days prior to initiation of study drug
- •Participant and/or caregiver willingness and ability to complete clinical outcome assessments throughout the study using either electronic, paper, or interviewer methods
- •For females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol
- •For males who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm, as defined by the protocol
排除标准
- •Medical history of: prior use of ALK inhibitors; diagnosis of Anaplastic Large Cell Lymphoma (ALCL); any gastrointestinal disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection; history of organ transplant; stem cell infusions as defined by the protocol
- •Substance abuse within 12 months prior to screening
- •Familial or personal history of congenital bone disorders, bone metabolism alterations, or osteopenia
- •Treatment with investigational therapy 28 days prior to initiation of study drug
- •Liver or kidney disease as defined by the protocol
- •National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade >/=3 toxicities attributed to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with alectinib
- •Co-administration of anti-cancer therapies other than those administered in this study
- •Active hepatitis B or C virus (HBV, HBC), or known HIV-positivity or AIDS-related illness
- •Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study
- •Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; such conditions should be discussed with the participant before trial entry
- •Planned procedure or surgery during the study except as permitted treatment as defined by the protocol
- •Infection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the participant upon induction of neutropenia, including participants who are, or should be, on antimicrobial agents for the treatment as active infection
- •Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of alectinib
研究组 & 干预措施
ALK-Fusion Positive
Experimental
Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
干预措施: Alectinib (Drug)
结局指标
主要结局
Percentage of Participants with Adverse Events
时间窗: Up to 10 years
Incidence of Participants with Dose-Limited Toxicities (DLTs)
时间窗: Cycle 1 (cycle length = 28 days)
Plasma Concentration of Alectinib
时间窗: Up to 10 years
Confirmed Objective Response Rate (ORR): Defined as the Proportion of Participants with Complete Response (CR) or Partial Response (PR) on two Consecutive Occasions >/= 4 Weeks Apart, as Determined by Blinded Independent Central Review (BICR)
时间窗: Up to 10 years
Plasma Concentration of Alectinib Metabolite (M4)
时间窗: Up to 10 years
次要结局
- Time to Response (TTR) as Determined by BICR and the Investigator(From the first dose of alectinib to the first documentation of objective response (CR or PR) (up to 10 years))
- Confirmed ORR as Determined by the Investigator(Up to 10 years)
- Progression-Free Survival (PFS) as Determined by BICR and the Investigator(From the first dose of alectinib to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 10 years))
- Overall Survival (OS)(From the first dose of alectinib to the date of death due to any cause (up to 10 years))
- Duration of Response (DOR) as Determined by BICR and the Investigator(From the first occurrence of a documented objective response (CR or PR) to disease progression or death from any cause, whichever occurs first (up to 10 years))
- Clinical Benefit Rate (CBR) as Determined by BICR and the Investigator(6 months after the first dose of alectinib)
研究者
研究点 (67)
Loading locations...
相似试验
招募中
1 期
Alectinib Pharmacokinetic in Patients With NSCLCNon-small Cell Lung Cancer Stage IIIBALK Gene MutationNCT05713006Instituto Nacional de Cancerologia de Mexico45
已完成
1 期
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaTumorsSolid Malignant TumorsOsteosarcomaDifferentiated Thyroid Cancer (DTC)NCT02432274Eisai Limited117
已完成
2 期
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03155009Hoffmann-La Roche44
已完成
2 期
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasPlexiform NeurofibromaNeurofibromatosis Type 1NCT03231306University of Alabama at Birmingham45
已完成
不适用
PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLCon-Small Cell Lung CancerJPRN-UMIN000015094ung Oncology Group in Kyushu, Japan (LOGIK)17